ClinicalTrials.gg
CompletedNCT04184700EPICMA IIUpdated Apr 14, 2026

Epigenetic Effects in Children With Cow's Milk Allergy Treated With Different Formulas

An interventional study of EHCF+LGG and RHF in Cow Milk Allergy, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 6 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Federico II University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
6 Months to 12 Months
Sex
All
01

Study summary

Lactobacillus GG (LGG) is able to exert long lasting effects in children with atopic disorders. Nutramigen LGG accelerates tolerance acquisition in infants with cow's milk allergy. The mechanisms of these effects are still largely undefined. The effect of LGG could be related at least in part by the immunoregulatory role played by LGG. This probiotic can balance the generation of cytokines possibly involved in IgE- or non-IgE-mediated cow's milk allergy Interleulkin (IL)-4, IL-5, IL-10, IFN-γ , TGF-β, and TNF-Υ), which can contribute to modulation of inflammatory processes. The investigators have demonstrated that children with IgE-mediated CMA produce significantly higher level of IL-4 and IL-13 in response to cow's milk protein, and that tolerance is associated with a marked reduction of IL-13 production and a concomitant increased frequency of IFN-γ releasing cells. Epigenetics studies the heritable (and potentially reversible) changes of the genome inherited from one cell generation to the next which alter gene expression but do not involve changes in primary DNA sequences, highlighting the complexity of the inter-relationship between genetics and nutrition. There are three distinct, but closely interacting, epigenetic mechanisms (histone acetylation, DNA methylation, and non-coding microRNAs) that are responsible for modifying the expression of critical genes associated with physiologic and pathologic processes. The profile of epigenetic modifications associated with Th lineage commitment, coupled with the sensitivity of the early developmental period, has led to speculation that factors that disrupt these pathways may increase the risk of allergic diseases. Specifically, effects on DNA methylation and endogenous histone deacetylase inhibitors acting on specific pathways (Th1 and T regulatory cell differentiation) may favour Th2-associated allergic differentiation. MicroRNAs are another structural components of an epigenetic mechanism of post-transcriptional regulation of messenger RNA translation. It has been recently identified a specific Th2-associated microRNA (miR-21) that is critical for the regulation of Th cell polarization. It has been previously demonstrated an inverse DNA methylation pattern of cytokines involved in Th2 response (IL-4, IL-5) compared with cytokines involved in Th1 response (IL-10, INF- y) in children with CMA acquiring oral tolerance, with the most pronounced effects in those treated with Nutramigen LGG.

02

Conditions studied

  • Cow Milk Allergy

Browse trials for

03

In context

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's enrollment of 90 is above the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Federico II University is the lead sponsor of 366 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children with cow's milk allergy

Exclusion criteria

Exclusion Criteria:

  • Concomitant chronic systemic diseases,
  • congenital cardiac defects,
  • active tuberculosis,
  • diseases,
  • immunodeficiency,
  • chronic inflammatory bowel diseases,
  • celiac disease,
  • cystic fibrosis,
  • metabolic diseases,
  • ,
  • chronic pulmonary diseases,
  • malformations of the gastrointestinal tract,
  • suspected eosinophilic esophagitis or eosinophilic enterocolitis,
  • suspected food-protein-induced enterocolitis syndrome,
  • suspected cow's milk protein-induced anaphylaxis,
  • still on exclusion diet with one of the study formulas or with another dietary regimen because of cow's milk allergy,
  • other food allergies.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    EHCF + LGG

    Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG

    Dietary Supplement: EHCF+LGG

  • Active comparator
    RHF

    Extensively hydrolyzed rice formula

    Dietary Supplement: RHF

  • Active comparator
    EHWF

    Extensively hydrolyzed protein formula

    Dietary Supplement: EHWF

  • Active comparator
    AAF

    Amino acid based formula

    Dietary Supplement: AAF

  • Active comparator
    SF

    Soy formula

    Dietary Supplement: SF

Interventions

  • Dietary supplementEHCF+LGG

    Drug page: Lacticaseibacillus rhamnosus GG

    Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG

  • Dietary supplementRHF

    Rice hydrolysed formula

  • Dietary supplementSF

    Soy formula

  • Dietary supplementEHWF

    extensively hydrolysed whey formula

  • Dietary supplementAAF

    amino acid based formula

06

What researchers measure

Primary outcomes

  1. Epigenetic modifications in cytokines genes

    TSDR demethylation (prop.) of FOXP3 in children with cow's milk allergy. The primary outcome was the time-averaged FoxP3 Treg-Specific-Demethylation-Region (TSDR) demethylation (prop.), which took into account three repeated measures (0,6,12 months).

    Time frame: 12 months

Secondary outcomes

  1. Epigenetic modifications in cytokines genes

    Demethtylation rate and expression (fc, fold change, ΔΔCt method)) of FOXP3 in children with cow's milk allergy

    Time frame: 6 and 12 months

  2. Epigenetic modifications in cytokines genes

    Methylation rate (%) of interleukin IL-4, IL-5, IL-10, IFN-γ, in children with cow's milk allergy

    Time frame: 6 and 12 months

  3. Epigenetic modifications in cytokines genes

    Serum levels (pg/ml) of interleukin IL-4, IL-5, IL-10, IFN-γ in children with cow's milk allergy

    Time frame: 6 and 12 months

  4. microRNAs modifications

    Expression of miR-125b miR-146a miR-155 miR-29a/b miR-27a miR-128 miR-21 miR-126 miR-145 miR-106a miR-193a5p miR-128

    Time frame: 12 months

  5. The rate of patients with immune tolerance acquisition to cow's milk protein

    Rate of patients with acquisition of tolerance to cow milk protein (rate of patients with outgrown cow's milk allergy)

    Time frame: 12 months

  6. Concentration of metagenomic characteristics of the intestinal microbiota

    evaluation of composition of gut microbiota

    Time frame: 12 months

  7. Concentration of metabolomic characteristics of the intestinal microbiota

    evaluation of function of gut microbiota

    Time frame: 12 months

07

Study locations

1 site
  • Pediatric Office
    Naples, 80100, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Dec 2023, 48 months.

Of 34 interventional studies with no phase under Milk Hypersensitivity, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2019
First posted
Dec 3, 2019
StartActual
Dec 10, 2019
Primary completionActual
Dec 31, 2023
CompletionActual
Aug 31, 2024
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04184700
Responsible party
Roberto Berni Canani, MD, PhD (Full professor, Federico II University) — Principal investigator
First posted
Dec 3, 2019
Start date
Dec 10, 2019
Primary completion
Dec 31, 2023
Completion
Aug 31, 2024
Last update
Apr 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lacticaseibacillus rhamnosus GG

Start the discussion